TNFRSF1A and neoplasm: To test this hypothesis in vivo, we challenged cohorts of C57BL/6J Nkg7+/+ and Nkg7-/- littermate mice with MC38-OVA-Tnfrsf1a-/- tumors and monitored tumor growth, with or without depletion of CD8+ T cells (Figures 6J, K).